Iza-bren and Tagrisso combination showed a 100% objective response rate in EGFR-mutant NSCLC at a 2.5 mg/kg dose. The 12-month progression-free survival and overall survival rates were 92% and 95%, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results